Intellectual Property and Life sciences attorney Jeff Ward recently authored the article, "Delisting Counterclaims in Hatch-Waxman Cases: An Ineffective Weapon to Address Improper Patent Listing" published in IPWatchdog on September 12.
In the article, Jeff discusses the challenges posed by improper patent listings under the Hatch-Waxman Act, a legislation aimed at striking a balance between pharmaceutical innovation and affordable drug access. The article delves into the statutory patent listing requirements, the importance of addressing listed patents, and the limitations of the current system in preventing abuses. Jeff also explores potential solutions, including the need for congressional action and expedited dispute resolution, to ensure the Act's goal of providing affordable drugs to patients is fully realized.
Click here to read the entire article.